Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy
Neonatal hypoxic ischemic encephalopathy (HIE) is a devastating disease that primarily causes neuronal and white matter injury and is among the leading cause of death among infants. Currently there are no well-established treatments; thus, it is important to understand the pathophysiology of the dis...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-09-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/16/9/22368 |
id |
doaj-6a36cd6d9881434ea4d1bfe94356514b |
---|---|
record_format |
Article |
spelling |
doaj-6a36cd6d9881434ea4d1bfe94356514b2020-11-25T00:46:41ZengMDPI AGInternational Journal of Molecular Sciences1422-00672015-09-01169223682240110.3390/ijms160922368ijms160922368Neuroprotective Strategies after Neonatal Hypoxic Ischemic EncephalopathyBrandon J. Dixon0Cesar Reis1Wing Mann Ho2Jiping Tang3John H. Zhang4Department of Physiology and Pharmacology, Loma Linda University School of Medicine, Loma Linda, CA 92354, USADepartment of Physiology and Pharmacology, Loma Linda University School of Medicine, Loma Linda, CA 92354, USADepartment of Physiology and Pharmacology, Loma Linda University School of Medicine, Loma Linda, CA 92354, USADepartment of Physiology and Pharmacology, Loma Linda University School of Medicine, Loma Linda, CA 92354, USADepartment of Physiology and Pharmacology, Loma Linda University School of Medicine, Loma Linda, CA 92354, USANeonatal hypoxic ischemic encephalopathy (HIE) is a devastating disease that primarily causes neuronal and white matter injury and is among the leading cause of death among infants. Currently there are no well-established treatments; thus, it is important to understand the pathophysiology of the disease and elucidate complications that are creating a gap between basic science and clinical translation. In the development of neuroprotective strategies and translation of experimental results in HIE, there are many limitations and challenges to master based on an appropriate study design, drug delivery properties, dosage, and use in neonates. We will identify understudied targets after HIE, as well as neuroprotective molecules that bring hope to future treatments such as melatonin, topiramate, xenon, interferon-beta, stem cell transplantation. This review will also discuss some of the most recent trials being conducted in the clinical setting and evaluate what directions are needed in the future.http://www.mdpi.com/1422-0067/16/9/22368neonatal hypoxic ischemic encephalopathyneuroprotectionintervention strategytherapeutic strategy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Brandon J. Dixon Cesar Reis Wing Mann Ho Jiping Tang John H. Zhang |
spellingShingle |
Brandon J. Dixon Cesar Reis Wing Mann Ho Jiping Tang John H. Zhang Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy International Journal of Molecular Sciences neonatal hypoxic ischemic encephalopathy neuroprotection intervention strategy therapeutic strategy |
author_facet |
Brandon J. Dixon Cesar Reis Wing Mann Ho Jiping Tang John H. Zhang |
author_sort |
Brandon J. Dixon |
title |
Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy |
title_short |
Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy |
title_full |
Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy |
title_fullStr |
Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy |
title_full_unstemmed |
Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy |
title_sort |
neuroprotective strategies after neonatal hypoxic ischemic encephalopathy |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2015-09-01 |
description |
Neonatal hypoxic ischemic encephalopathy (HIE) is a devastating disease that primarily causes neuronal and white matter injury and is among the leading cause of death among infants. Currently there are no well-established treatments; thus, it is important to understand the pathophysiology of the disease and elucidate complications that are creating a gap between basic science and clinical translation. In the development of neuroprotective strategies and translation of experimental results in HIE, there are many limitations and challenges to master based on an appropriate study design, drug delivery properties, dosage, and use in neonates. We will identify understudied targets after HIE, as well as neuroprotective molecules that bring hope to future treatments such as melatonin, topiramate, xenon, interferon-beta, stem cell transplantation. This review will also discuss some of the most recent trials being conducted in the clinical setting and evaluate what directions are needed in the future. |
topic |
neonatal hypoxic ischemic encephalopathy neuroprotection intervention strategy therapeutic strategy |
url |
http://www.mdpi.com/1422-0067/16/9/22368 |
work_keys_str_mv |
AT brandonjdixon neuroprotectivestrategiesafterneonatalhypoxicischemicencephalopathy AT cesarreis neuroprotectivestrategiesafterneonatalhypoxicischemicencephalopathy AT wingmannho neuroprotectivestrategiesafterneonatalhypoxicischemicencephalopathy AT jipingtang neuroprotectivestrategiesafterneonatalhypoxicischemicencephalopathy AT johnhzhang neuroprotectivestrategiesafterneonatalhypoxicischemicencephalopathy |
_version_ |
1725263786316660736 |